Results 291 to 300 of about 569,881 (316)

Immunotherapy for Acute Myeloid Leukemia

Seminars in Hematology, 2015
Despite longstanding efforts in basic research and clinical studies, the prognosis for patients with acute myeloid leukemia (AML) remains poor. About half of the patients are not medically fit for intensive induction therapy to induce a complete remission and are treated with palliative treatment concepts.
Lichtenegger, F.S., Krupka, C., Köhnke, T., Subklewe, M.   +3 more
openaire   +3 more sources

Childhood Acute Myeloid Leukemia

Current Treatment Options in Oncology, 2008
Despite the use of intensive chemotherapy and hematopoietic stem cell transplantation, approximately one-third of children with acute myeloid leukemia (AML) still suffer relapse of their disease. It is unlikely that improvements in outcome can be achieved by further intensification of conventional chemotherapy.
openaire   +2 more sources

Pediatric acute myeloid leukemia

Expert Review of Anticancer Therapy, 2012
Pediatric acute myeloid leukemia (AML) is currently associated with survival rates as high as 70%. However, many events still occur, side effects are significant, and late effects occur and can even be life-threatening. Thus, the treatment of pediatric AML still needs further improvement.
openaire   +6 more sources

Acute Myeloid Leukemia

American Nurse Journal
Thorough nursing assessment and follow-up lead to escalation of care.
Dr Shruti Chauhan, Dr Sachin Sharma, Dr Mayank Chauhan   +2 more
  +4 more sources

Human medicines European public assessment report (EPAR): Vanflyta, quizartinib, Leukemia, Myeloid, Acute, Date of refusal: 19/12/2019, Status: Refused

Case Medical Research, 2020

semanticscholar   +1 more source

Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Myelodysplastic Syndromes,Leukemia, Myelomonocytic, Chronic,Leukemia, Myeloid, Acute, Date of authorisation: 13/02/2020, Status: Authorised

Case Medical Research, 2020

semanticscholar   +1 more source

Acute Myeloid Leukemia

New England Journal of Medicine, 1999
Löwenberg, Bob, Downing, JR, Burnett, A
openaire   +3 more sources

Human medicines European public assessment report (EPAR): Xospata, gilteritinib, Leukemia, Myeloid, Acute, Date of authorisation: 24/10/2019, Status: Authorised

Case Medical Research, 2019

semanticscholar   +1 more source

Human medicines European public assessment report (EPAR): Azacitidine Celgene, azacitidine, Myelodysplastic Syndromes,Leukemia, Myelomonocytic, Chronic,Leukemia, Myeloid, Acute, Date of authorisation: 02/08/2019, Status: Authorised

Case Medical Research, 2019

semanticscholar   +1 more source

Human medicines European public assessment report (EPAR): Vyxeos, daunorubicin / cytarabine, Leukemia, Myeloid, Acute, Date of authorisation: 23/08/2018, Revision: 1, Status: Authorised

Case Medical Research, 2019

semanticscholar   +1 more source